Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Inclusion Criteria:

• Patient diagnosed with chronic (ITP with > 1 year duration) primary ITP living inthe USA or the UK:

• On ITP pharmacologic treatment, , including on-demand treatment strategy,regardless of last platelet count (below or above 100 x 10^9 counts/L);

• Patients with their most recent platelet count >50 x 109 counts/L) and withoutany ITP-specific treatment for 1 year or less.

• Adult patient who are 18 years or older at index date

• Patient who has received at least one initial first line ITP therapy (CS/ IVIg/ANTId) with initial response as of index date and indicated by one of the following:

• Platelet count ≥ 50 x 10^9 counts /L; OR

• Platelet count ≥ 30 x 10^9 counts /L with at least a two-fold increase frombaseline within 1 month since start of treatment, as per ASH 2019 guidelines;OR

• A medical record of initial response as determined by clinical judgement,considering documented platelet count along with overall patient condition andrelevant medical factors.

• Patients whose medical history related to the study objectives are available fromthe site covering 12 months prior to index date.

• Patient provided informed consent to participate in the study.

Exclusion Criteria:

• Secondary ITP.

• Patients with their most recent platelet count >50 x 10^9 counts/L and without anyITP-specific treatment for more than 1 year.

• Patients with recent or active infection recorded 14 days or less before index date;patients with uncontrolled chronic infections or who were recently diagnosed with achronic infection (≤14 days of index date).

• Patients with vaccination in 28 days before index date.

• Patients treated with rilzabrutinib on or before index date.

• Patients who participated in an interventional clinical trial for anyinvestigational drug in the 180 days prior to index date.